Meet Scailyte at BioTech X at Booth #37 in Basel Congress Center from 8th to 10th November 2022
Meet Scailyte at BioTech X in Basel Congress Center from 8th to 10th November 2022
Meet Scailyte at BioTechX at booth #37 in Basel Congress Center Basel, November 8-10th 2022.
You can register for the event here: https://www.terrapinn.com/conference/biotechx/index.stm
BioTechX is Europe’s largest congress covering diagnostics, precision medicine and digital transformation in pharmaceutical development and healthcare.
BioTechX successfully brings together an amalgamation of genomics, translational medicine, data scientists, IT, bioinformaticians, cheminformaticians, clinicians, healthcare and pharma companies. The event will showcase innovation, demonstrate success and break through the obstacles and barriers to ensure that the innovations in genomics and big data, enter the clinic with speed and efficiency.
Join us and be part of the story in 2022 with 400 speakers and 2,000+ attendees.
Meet the team attending:
Shaoline holds a Master’s in Bioinformatics from the University of Lausanne. After working for three years as a Bioinformatician at EPFL, she joined Scailyte in 2021 as a Data Analyst. At Scailyte, she is currently working on the discovery of molecular markers for the diagnosis of Endometriosis.
Sarah Carl is the Director of Data Science at Scailyte, where she leads a team of data scientists committed to developing Scailyte’s AI-driven single-cell analytics platform, ScaiVision, as well as driving data analysis for Scailyte’s biomarker discovery projects, with the goal of advancing precision medicine. Sarah holds a BA in Biology from the University of Chicago and a PhD in Genetics from the University of Cambridge. She previously worked as a bioinformatician at the Friedrich Miescher Institute in Basel, Switzerland, for four years before joining Scailyte in 2018.
Dennis Göhlsdorf has degrees in Biochemistry and Computer Science, obtained at the University of Tuebingen. He has acquired a PhD at the Institute of Neuroinformatics at ETH Zurich / University of Zurich. From 2013 until 2016 he was a Software engineer at Google Germany, working on Image processing algorithms. Since 2016 Dennis is a Co-Founder of Scailyte and is currently working in the data science team.
Angelo Duò is a Data Scientist at Scailyte since 2018.
Martijn van Attekum is trained as a medical doctor and obtained a PhD in oncology. He has worked on a variety of biomedical AI topics, such as protein feature prediction or patient stratification using image analysis. At Scailyte, Martijn has developed ScaiVision, the AI-driven discovery platform for ultra-sensitive biomarkers from single-cell omics and clinical data modalities.
Dr. Diana Stoycheva is a principal expert scientist at Scailyte with a focus on immuno-oncology. She obtained her PhD in Berlin in anti-tumor immunotherapy. She pursued postdoctoral studies in immunology at the ETH Zurich before joining Scailyte in 2020 to evaluate opportunities for the application of cutting-edge single-cell technologies for biomarker discoveries in immunology and immuno-oncology.
Corinne obtained a Masters in Engineering Sciences in Biotechnology and a PhD in Immunology from Université Paul Sabatier in Toulouse, France. She pursued postdoctoral studies at the City of Hope National Medical Center in the U.S.A. in the field of nuclear receptor biochemistry before joining Roche Pharmaceuticals. There, she held various positions in early research and development, intersecting with translational biomarker science, cutting-edge “omics” technologies and innovation. She joined Scailyte in 2021 as Chief Operating Officer.
Vijay Tiwari
Vijay is a Professor in Genomics at QUB, working on achieving an integrated molecular and systems-level understanding of cancer and neurological disorders.
Justyna is a molecular biologist with a PhD in Clinical Medicine Research from Imperial College London. After working as a Postdoctoral Fellow in cancer research at the DKFZ in Germany and the University Children’s Hospital in Zurich, she joined Scailyte in 2022 as a Scientist in precision medicine. Currently she is working as a Business Development Associate, helping to build the next phase of Scailyte’s growth.
Filipa has a PhD in Biomedical Sciences having worked on a variety of topics at the crossroads of host-pathogen interaction. Filipa has a passion for deep-tech innovation and entrepreneurship. At Scailyte she is part of the business development team.
Julian is a senior data scientist at Scailyte with a focus on immunoinformatics and T-cell biology. He obtained his PhD in New Zealand in bacterial stress responses. He was a postdoctoral fellow and bioinformatician specialising in T-cell immunology at the University of Basel before joining Scailyte in 2022 to discover biomarkers and profile immune repertoires.
About Scailyte
Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets.
Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.
Recent News
Scailyte is fundraising!
Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Recent News
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Recent News
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
Recent News
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...
Recent News
Scailyte is fundraising!
Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Recent News
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...